[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Belgrade\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,49,76,105,125,157,183,207,232,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644469","bone-substitutes-and-nipsa-in-intrabony-periodontal-defects-a-randomized-controlled-trial-100644469",false,"NCT07671963","Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial","Regenerative Therapy of Intrabony Periodontal Defects Using Bone Substitutes and a Minimally Invasive Nonincised Papilla Surgical Approach - A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of Stage III periodontitis\n* At least one intrabony periodontal defect with probing depth \\> 5 mm following completion of non-surgical periodontal therapy\n* Full-mouth plaque score (FMPS) \\\u003C 20%\n* Full-mouth bleeding score (FMBS) \\\u003C 20%\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Systemic medical contraindications to periodontal surgery\n* History of head and neck radiotherapy\n* Poor oral hygiene or lack of motivation\u002Fcompliance\n* Uncontrolled diabetes mellitus\n* Pregnancy or lactation\n* Treatment with antiresorptive medications or other drugs affecting bone remodeling\n* Heavy smoking (\\>20 cigarettes\u002Fday)",true,"ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter randomized controlled clinical trial aims to compare the clinical, radiographic, microbiological and molecular outcomes of two collagenated xenogeneic bone substitutes (GTO® and GenOs®) used in combination with the Non-Incised Papilla Surgical Approach (NIPSA) for the treatment of intrabony periodontal defects. The study will evaluate whether differences exist between the two biomaterials with respect to clinical attachment gain, defect resolution, wound healing and biological markers of regeneration.",[28,29,30],"Periodontitis (Stage 3)","Minimally Invasive Surgical Procedures","Bone Substitutes",[32,33,34,35],"periodontitis","regenerative treatment","NIPSA","bone substitutes","RECRUITING","2026-06-22",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":22},"2026-07-01",{"date":44,"type":22},"2027-03-01",{"name":46,"class":47},"University of Belgrade","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100624806","oral-dynamic-propulsion-appliance-in-treatment-of-patients-with-obstructive-sleeping-apnea-100624806","NCT07414420","Oral Dynamic Propulsion Appliance in Treatment of Patients With Obstructive Sleeping Apnea","Treatment Effects of Oral Dynamic Propulsion Appliance During the Sleeping Phase in Patients With Obstructive Sleeping Apnea","Inclusion Criteria:\n\n* age between 20 and 65 years\n* clinically confirmed diagnosis of mild or moderate obstructive sleep apnea (Apnea hypopnea index 15-30 episodes\u002Fhour)\n* sufficient number of periodontally healthy teeth to support the oral appliance\n* written informed consent of conformance with the study protocol\n\nExclusion Criteria:\n\n* age bellow 20 and over 65 years\n* patients not able or not willing to follow the study protocol\n* patients with severe OSA (Apnea hypopnea index \\> 30 episodes\u002Fhour) and\u002For some other breathing disturbances\n* patients with psychiatric, neurological or psychosomatic disorders\n* patients with Body Mass Index \\> 29kg\u002Fsqm\n* pregnancy\n* presence of the anatomical obstruction in the airways\n* severe periodontal disease (III and IV grade)\n* pathological changes in the structures of TMJ, muscles or ligaments\n* mandibular protrusion less than 3mm\n* orthodontic anomalies, malocclusions, II and III skeletal class, and orthodontic appliances","20 Years","65 Years",{"count":59,"type":22},40,[25],"Obstructive Sleep Apnea (OSA) is one of the most prevalent sleep disorders, affecting nearly one billion people worldwide. It is characterized by repeated episodes of complete (apnea) or partial (hypopnea) obstruction of the upper airway during sleep, leading to snoring, excessive daytime sleepiness, insomnia, morning headaches, nocturia, behavioral changes, reduced concentration, and serious cardiovascular and metabolic complications such as insulin resistance, type II diabetes, and metabolic syndrome. During the night, patients may experience up to a hundred apnea or hypopnea events lasting from 10 to 120 seconds. Therapy for OSA depends on its severity, defined by five or more obstructive events per hour of sleep. Over the past decade and a half, oral appliances (OAs) have become the treatment of choice for mild to moderate forms of OSA due to their efficacy and comfort. For this purpose, the DYNAMIC PROPULSION ORAL APPLIANCE (DPOA) has been designed with a mechanism that provides controlled, gentle, gradual and automatic mandible movement in propulsion during sleep. Unlike conventional OAs that fix the mandible in only one propulsive position, causing stress to orofacial complex and upper airway structures such as masticatory muscles and the temporomandibular joints, the DPOA provides gradual, automatic mandibular movement to the previously determined propulsive position. This gradual adaptation minimizes stress, reduces side effects, and enhances treatment success. In that way, the DPOA enables complete functional adaptation of the orofacial system and upper airway structures, leading to improved patient comfort and better therapeutic outcome.\n\nThe primary objective of the study is to determine the effectiveness of OSA therapy in patients with skeletal Class I (eugnathic jaw relationship) using a DYNAMIC PROPULSION ORAL APPLIANCE (DPOA) with a mechanism that provides controlled, gentle, gradual and automatic mandible movement in propulsion during sleep.",[63],"Obstructive Sleep Apnea (OSA)",[65],"obstructive sleep apnea, oral apparatus","NOT_YET_RECRUITING","2026-02-13",{"date":69,"type":40},"2026-02-18",{"date":71,"type":22},"2026-03",{"date":73,"type":22},"2027-09",{"name":46,"class":47},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100624807","validation-of-blood-based-biomarkers-in-tace-treated-hepatocellular-carcinoma-100624807","NCT07414433","Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma","Blood-Based Biomarkers for Prediction and Monitoring of Response to TACE in Hepatocellular Carcinoma","BLOOD-TACE-M","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of hepatocellular carcinoma (HCC) based on LI-RADS CT\u002FMRI v2018 criteria or histopathological verification\n* Candidate for TACE as part of standard treatment (BCLC criteria)\n* Child-Pugh score ≤ 7 at the time of TACE indication\n* ECOG performance status 0 at the time of TACE indication\n* Availability of at least one follow-up multiphase CT or MRI scan 4-8 weeks after TACE\n\nExclusion Criteria:\n\n* Child-Pugh score ≥8 at the time of TACE indication\n* Eastern Cooperative Oncology Group (ECOG) performance status \\> 0 at the time of TACE indication.\n* Presence of extrahepatic dissemination and\u002For macrovascular invasion\n* Technically unfeasible TACE (e.g., inability to identify feeder artery)\n* Severe uncorrectable coagulopathy or cytopenia\n* Severe allergy or contraindication to iodine contrast agent or drugs used during TACE\n* Pregnancy or breastfeeding\n* Inability to provide signed informed consent",{"count":85,"type":22},60,"OBSERVATIONAL","The goal of this prospective observational study is to validate the clinical utility of specific blood-based biomarkers for predicting and monitoring treatment response in patients with hepatocellular carcinoma (HCC) undergoing Transarterial Chemoembolization (TACE).\n\nThe study aims to determine if longitudinal changes in these biomarkers can reliably correlate with early radiological treatment response, as measured by Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Participants will receive standard-of-care TACE treatment and will provide blood samples at baseline and during subsequent clinical follow-up cycles. Biomarker levels will be compared against routine multiphase computed tomography (CT) or Magnetic Resonance Imaging (MRI) scans performed four to eight weeks post-procedure to establish their accuracy as predictive tools for clinical success.",[89,90],"Hepatocellular Carcinoma (HCC)","Liver Neoplasms",[92,93,94,95,96],"Hepatocellular Carcinoma","TACE","Biomarkers","mRECIST","Drug-Eluting Beads","2026-02-09",{"date":99,"type":40},"2026-02-17",{"date":101,"type":22},"2026-03-01",{"date":103,"type":22},"2029-12-30",{"name":46,"class":47},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":75},"100622060","exploratory-blood-based-biomarkers-in-tace-treated-hepatocellular-carcinoma-100622060","NCT07378709","Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma","Blood-Based Biomarkers for Prediction and Monitoring of Response to TACE in Hepatocellular Carcinoma: A Pilot Study","BLOOD-TACE-P",{"count":113,"type":22},15,"The goal of this observational study is to evaluate changes in selected biomarkers and their potential connection with early radiological outcomes in adult patients with hepatocellular carcinoma (HCC) who are candidates for Transarterial Chemoembolization (TACE) treatment. The main questions it aims to answer are whether specific biomarkers change in response to TACE treatment and if there is a correlation between these changes and early radiological treatment response as measured by Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Participants will undergo standard-of-care TACE as decided by a multidisciplinary team and will provide blood samples at predefined, clinically relevant time points, specifically before the first TACE procedure and during subsequent follow-up cycles on the day of either a new TACE or a control Computed Tomography (CT) scan. Additionally, participants will undergo routine clinical and radiological assessments, including multiphase CT or Magnetic Resonance Imaging (MRI) scans four to eight weeks after the procedure to monitor treatment success, with all data being collected from medical records and standard diagnostic procedures.",[89,90],[92,93,94,95,96],"2026-02-02",{"date":119,"type":40},"2026-02-05",{"date":121,"type":40},"2024-08-21",{"date":123,"type":22},"2026-06-01",{"name":46,"class":47},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":75},"100618229","steroid-treatment-to-prevent-thoracic-endovascular-aortic-repair-postimplantation-syndrome-100618229","NCT07328906","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome (STOP TEVAR PIS): A Randomized, Double-Blind, Placebo-Controlled Trial","STOP TEVAR PIS","Inclusion Criteria:\n\n* Consecutive patients admitted due to endovascular treatment of aortic dissection type B or thoracoabdominal aortic aneurysm in whom elective, open repair is planned.\n* Patients capable of giving informed consent.\n* Patients who are estimated to be available for long-term follow-up.\n\nExclusion Criteria:\n\n* emergency procedures, the existence of severe renal insufficiency (serum creatinine \\>176 µmol\u002FL or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2), severe liver insufficiency (ALT value more than twice the upper limit or bilirubin levels more than twice the reference values), uncontrolled diabetes mellitus (fasting glycemia above 13.9 mmol\u002FL, i.e. the value glycosylated hemoglobin over 8.5%), existence of active infection or sepsis, autoimmune disease, chronic pain syndromes, proven allergy to methylprednisolone, existence of gastric or duodenal ulcer, immunosuppressive or chemotherapy in the previous three months, active malignant disease, genetic diseases of connective tissue, pregnancy, critical lower limb ischemia, previous endovascular procedure on the aorta, preoperative administration of corticosteroids for any reason, significantly impaired cognitive status or psychiatric illness, acute peri\u002Fmyocarditis, advanced heart failure, as well as voluntary refusal to participate in the study","90 Years",{"count":135,"type":22},174,[25],"Postimplantation syndrome (PIS) is a common and clinically important complication following thoracic endovascular aortic repair (TEVAR). PIS is characterized by a strong systemic inflammatory response to the stent-graft implantation and is manifested by flu-like symptoms, which include fever, increased white blood count, increased levels of acute phase proteins, and fatigue, but without a clear inflammatory and infective cause. Besides, it has been demonstrated that PIS is associated with prolonged hospital stay and increased risk for postoperative complications, including acute kidney injury, postoperative delirium, and increased postoperative pain scores. Recently, there has been increasing evidence that PIS is associated with an increased risk of major adverse cardiac events (MACE) and perioperative myocardial injury. Observational studies suggest that preoperative administration of glucocorticoids may decrease the incidence of PIS after TEVAR and EVAR procedures. However, to date, there are no randomised trials that have investigated whether preoperative administration of glucocorticoids can reduce the incidence of PIS and its associated poorer treatment outcomes following TEVAR. This randomized controlled trial was designed to investigate the effect of glucocorticoid administration on reducing the incidence and improving the outcome of patients who develop PIS after TEVAR.",[139,140,141,142],"Postimplantation Syndrome","Myocardial Injury","MACE","Mortality",[144,145,146,147,141,148],"postimplantation syndrome","methylprednisolone","TEVAR","myocardial injury","mortality","2026-01-08",{"date":151,"type":40},"2026-01-12",{"date":153,"type":22},"2026-01",{"date":155,"type":22},"2029-01",{"name":46,"class":47},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":75},"100561727","polyoxymethylene-pom-in-the-production-of-telescopic-denture-in-older-adults-with-subtotal-edentulism-100561727","NCT06593925","Polyoxymethylene (POM) in the Production of Telescopic Denture in Older Adults With Subtotal Edentulism","Assessment of Polyoxymethylene (POM) as a Material for the Outer Crowns and Telescopic Denture's Framework in the Treatment of Subtotal Edentulism","Inclusion Criteria:\n\n* patients aged 65 and over\n* patients with subtotal edentulism\n* patients who sign an informed consent for participation in the study\n* retention teeth must have a minimum crown\u002Froot ratio of 1:1\n* retention teeth must have sufficient tooth substance (at least two walls)\n\nExclusion Criteria:\n\n* patients younger than 65 years\n* patients with temporomandibular joint dysfunction\n* patiens with bruxism\n* presence of intrabony defects around the retention teeth\n* presence of pathological tooth mobility\n* presence of periapical inflammatory processes, abscesses and fistulas in the region of retention teeth\n* presence of fetor and suppuration from periodontal pockets of retention teeth","100 Years",{"count":59,"type":22},[25],"The mail goal of this study is to evaluate the success of the prosthetic treatment with telescopic removable partial denture with framework made of polyoxymethylene (POM). In accordance with the growing older population, who often require complex dental care, it is very important to test simple yet effective and safe solutions. Bearing in mind that POM has proven to be a good solution for conventional removable partial dentures with clasps (RPD), and that it is quite common to have 2-3 remaining teeth, a denture with a framework made of light and flexible material such as POM present a good solution. The hypothesis is that a POM telescopic denture is clinically as adequate, effective and safe as the conventional complex cobalt chromium molybdenum alloy denture with clasps. Telescopic denture should provide better comfort and longevity compared to conventional RPD because of axial loading of the abutment teeth and no negative biological effect of clasps. Moreover, conventional telescopic denture is made of precious alloys which increase their cost; therefore, POM telescopic denture present great advantage in cost\u002Feffective treatment. Telescopic crowns are comprised of inner and outer crowns; accordingly, telescopic denture represent a type of complex denture where one part is fixed on the remaining teeth (inner crowns) and other part (outer crowns and denture framework) is removable.\n\nThe key factors that will define the success of the treatment will be: assessment of dentures' retention, oral health related quality of life, presence of biological complications, presence of mechanical complications, denture appearance and chewing function assessment.",[169],"Subtotal Edentulism",[171,172,173,174],"polyoxymethylene","double crowns","telescopic denture","conventional complex partial denture with clasps","2024-09-09",{"date":177,"type":40},"2024-09-19",{"date":179,"type":40},"2024-01-30",{"date":181,"type":22},"2027-01",{"name":46,"class":47},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":75},"100556534","immediate-vs-conventional-loading-for-early-implant-placement-100556534","NCT06526351","Immediate vs Conventional Loading for Early Implant Placement","Immediate Vs. Conventional Loading for Early Implant Placement in the Esthetic Zone of Maxilla: Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Single failing tooth in the esthetic zone of maxilla (second premolar to second premolar)\n* Patients older than 18 years\n* Healthy patients ASA I and II\n* Non-smokers\u002FLight smokers (\\\u003C10 cigarettes per day)\n* Adequate bone volume apical and palatal to the failing tooth to allow for sufficient primary - implant stability of regular diameter implant\n\nExclusion Criteria:\n\n* Implants adjacent to the failing teeth\n* Active periodontal infection\n* Severe bruxism\n* Systemic or local conditions that contraindicates dental implant surgery - Heavy smokers (\\>10 cigarettes per day)",{"count":191,"type":22},50,[25],"The goal of this study is to assess clinical, radiological and patient centred outcomes of immediate and conventional implant loading protocols, and to compare clinical outcomes of these two different loading protocols (immediate and conventional) in combination with early implant placement of single implants in the esthetic zone of maxilla.",[195],"Dental Implant",[197,198],"early implant placement","immediate provisionalization","2024-07-27",{"date":201,"type":40},"2024-07-29",{"date":203,"type":40},"2024-03-29",{"date":205,"type":22},"2027-03",{"name":46,"class":47},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":215,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":48},"100532576","anti-inflammatory-diet-in-brc-patients-on-aromatase-inhibitors-100532576","NCT06214598","Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors","Anti-Inflammatory Dietary Intervention in Breast Cancer Patients Receiving Aromatase Inhibitors","AID","Inclusion Criteria:\n\n* Age: 45 to 70 years\n* Postmenopausal women\n* Histologically confirmed BRC, stage I to IIIa\n* ER positive \u002FHER2 negative\n* Application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months\n* Body mass index from 20 to 34.9 kg\u002Fm 2\n* Able to understand the requirements of the study and provide written information consent\n\nExclusion Criteria:\n\n* Metastatic or locally advanced disease\n* HER2-positive tumors\n* Presence of other malignant or serious chronic diseases\n* Active infections\n* Previous stroke or heart attack,\n* Rheumatoid arthritis and other types of autoimmune diseases\n* Presence of a significant neurological deficit\n* Dementia\n* Allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits.\n* Allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant)\n* Use of lipid-lowering drugs (statins, Normolip)\n* Current use of warfarin or other anticoagulants\n* Corticosteroid therapy for the last month\n* Use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study","FEMALE","45 Years","70 Years",{"count":219,"type":22},90,[25],"This project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.",[223],"Breast Cancer","2024-05-07",{"date":226,"type":40},"2024-05-09",{"date":228,"type":40},"2024-03-01",{"date":230,"type":22},"2026-11-30",{"name":46,"class":47},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":239,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":75},"100538707","noise-oxidative-stress-and-cardiovascular-system-100538707","NCT06294340","Noise, Oxidative Stress and Cardiovascular System","NOXYCARD","Inclusion Criteria:\n\n* age 18-65\n* both genders\n* good self-reported health\n\nExclusion Criteria:\n\n* diabetes mellitus\n* arterial hypertension or other cardiovascular diseases\n* kidney diseases\n* pregnancy\n* malignant diseases\n* mental diseases",{"count":240,"type":22},150,"Environmental noise represents a health problem for at least one in five citizens of the European Union. Noise exposure leads to the development of arterial hypertension, myocardial infarction, stroke, and obesity. Given the limited information on noise exposure and noise effects on humans in the Republic of Serbia, the overall objective of NOXYCARD is to collect environmental noise levels data; to identify long-term and short-term noise effects on the cardiovascular system; and to evaluate the levels of blood stress hormones, oxidative stress, and inflammation in individuals with normal body weight and individuals with obesity.",[243,244],"Noise; Adverse Effect","Noise Exposure","2024-02-27",{"date":247,"type":40},"2024-03-05",{"date":249,"type":22},"2025-01",{"date":251,"type":22},"2028-12",{"name":46,"class":47},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":75},"100490303","the-use-of-coronary-displaced-flap-and-deepithelialized-free-graft-in-the-treatment-of-multiple-gingival-recessions-100490303","NCT05664373","The Use of Coronary Displaced Flap and Deepithelialized Free Graft in the Treatment of Multiple Gingival Recessions","The Use of Coronary Displaced Flap and Deepithelialized Free Graft in the Treatment of Multiple Adjacent Gingival Recessions - A Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Age between 18 and 60 years,\n* Non-smokers or consumption of up to 10 cigarettes per day,\n* no signs of gingival inflammation,\n* Presence of at least two single-rooted teeth with type I gingival recession ≥2 mm deep on the buccal side on both sides of the jaw,\n* Plaque index (PI) and gingival bleeding on provocation (BOP) \\\u003C15% and probing depth (PPD) \\\u003C3 mm,\n* Absence of non-carious cervical lesions (NCL) and undetectable cemento-enamel junctionr (CEJ) at defect sites,\n* No history of previous periodontal plastic surgery on the affected teeth.\n\nExclusion Criteria:\n\n* Presence of carious lesions or restorations in the CEJ area,\n* Use of medications that affect periodontal health and healing,\n* Medical contraindications for periodontal surgical procedures,\n* Pregnancy and breastfeeding.","60 Years",{"count":191,"type":22},[25],"Successful treatment of multiple gingival recessions (MRG) is a major challenge in periodontal plastic surgery due to complicated predisposing anatomical features of the surrounding tissues, such as a thin gingival phenotype or a limited zone of keratinized gingiva, variations in the depth and width of adjacent gingival recessions, shallow vestibulum and coronally inserted frenums and\u002For plica.The application of coronary advanced flap (CAF) or tunnel technique (TUN) with connective tissue graft (CTG) gives the best results in the therapy of MRG The application of connective tissue grafts in combination with various surgical techniques is accepted as the \"gold standard\" in GR therapy. A limitation in the application of CTG is the limited region of the donor site, especially in cases where a larger dimension of the CTG is required, or if the thickness of the hard palate tissue is inadequate. Techniques for obtaining subepithelial CTG (S-CTG), whether it is the trap-door technique or the single incision technique, are often associated with postoperative pain and discomfort, as well as necrosis\u002Fdehiscence of the palatal flap at the donor site.\n\nIn order to overcome these limitations and obtain a firmer and more uniform CTG, especially when the thickness of the palatal tissue is inadequate (≤2.5 mm) and when a large dimension of the graft in the apico-coronary or mesio-distal direction is required, deepithelialization of the free gingival graft has been proposed (D-FGG). D-FGG has also been shown to be less prone to postoperative contraction, as it consists predominantly of collagen-rich connective tissue from the lamina propria, while adipose\u002Fglandular tissue is minimally represented. FGG can be deepithelialized intraorally with a diamond bur or diode laser, or extraorally with a scalpel. Despite all the biological advantages of D-FGG, there is scarce evidence in the literature about its histological characteristics after intraoral and extraoral deepithelialization, as well as the clinical outcomes of grafts thus obtained in combination with CAF in the treatment of MGR. Therefore, this aims of the study are to investigate the clinical efficacy and postoperative patient morbidity using D-FGG and modified CAF in the treatment of MGR, as well as to evaluate the histological characteristics of grafts obtained using two different deepithelialization techniques.",[265],"Gingival Recession Generalized Moderate",[267,268,269,270],"gingival recession","deepithelialized free gingival graft","coronally advanced flap","epithelial remnants","2022-12-17",{"date":273,"type":40},"2022-12-23",{"date":275,"type":40},"2022-11-01",{"date":277,"type":22},"2034-12-10",{"name":46,"class":47},""]